Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease

Pharmacotherapy - Tập 20 Số 1 - Trang 1-12 - 2000
Michael W. Jann1
1Departments of Pharmacy Practice and Pharmaceutical Sciences, Mercer University, Southern School of Pharmacy, Atlanta, Georgia.

Tóm tắt

Rivastigmine is a cholinesterase inhibitor (ChEI) with a structural formula different from that of currently available ChEIs. Tacrine and donepezil are classified as short‐acting or reversible agents since binding to acetylcholinesterase enzyme (AChE) is hydrolyzed within minutes. Rivastigmine is classified as an intermediate‐acting or pseudo‐irreversible agent due to its long inhibition on AChE of up to 10 hours. Preclinical biochemical studies indicated that rivastigmine has central nervous system selectivity over peripheral inhibition. It ameliorated memory impairment in rats with forebrain lesions. The drug is rapidly absorbed orally, with a bioavailability of 0.355 and low protein binding (40%). Its elimination half‐life is less than 2 hours, and it is converted to an inactive metabolite at the site of action, bypassing hepatic metabolic pathways. Its disposition essentially is unaltered in patients with renal or hepatic impairment. It also has dose‐dependent effects on AChE inhibition. In the two large multicenter clinical trials (total 1324 patients) that used a forced‐dosage titration scheme, rivastigmine 6–12 mg/day was superior to placebo on three cognitive and functioning scales (p<0.001). Gastrointestinal symptoms are the most frequently reported adverse events. They occurred mostly during the dosage titration phase and decreased during the maintenance phase. Rivastigmine offers clinicians another therapeutic agent to treat Alzheimer's disease.

Từ khóa


Tài liệu tham khảo

Jann MW, 1998, PSAP, 27

Small GW, 1997, Diagnosis and treatment of Alzheimer's disease and related disorders, JAMA, 278, 1363

10.2165/00023210-199911030-00005

10.2165/00002512-199914050-00004

10.1254/jjp.74.225

Jann MW, 1998, Preclinical pharmacology of metrifonate, Pharmacotherapy, 18, 55S, 10.1002/j.1875-9114.1998.tb03879.x

10.1016/S0149-2918(98)80127-6

10.2165/00002512-199813050-00005

Anand R., 1996, Clinical development of Exelon (ENA 713): the ADENA programme, J Drug Dev Clin Pract, 8, 9

Enz A., 1994, Alzheimer's disease. Therapeutic strategies, 211

Weinstock M., 1997, Possible role of the cholinergic system and disease models, J Neural Transm, 49, 93

Weinstock M., 1994, Pharmacologic evaluation of phenyl‐carbamates as CNS selective acetylcholinesterase inhibitors, J Neural Transm, 43, 219

Anand R., 1996, Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview, J Drug Dev Clin Pract, 8, 1

Enz A., 1994, Alzheimer's disease. Therapeutic strategies, 125, 10.1007/978-1-4615-8149-9_22

10.1016/S0079-6123(08)62429-2

Giacobini E., 1994, Alzheimer's disease. Therapeutic strategies, 247, 10.1007/978-1-4615-8149-9

10.1111/j.1600-0404.1998.tb00645.x

10.2165/00002512-199914030-00004

Games D., 1997, Alzheimer‐type neuropathology in transgenic mice overexpressing V71F β‐amyloid precursor protein, Nature, 336, 523

10.1016/0278-5846(94)00113-V

10.1111/j.1749-6632.1991.tb00232.x

10.1007/BF01705533

10.1016/S0006-8993(97)00982-7

Tanaka K., 1993, Effects of the acetylcholinesterase inhibitor ENA‐713 on ischemia‐induced changes in acetylcholine and aromatic amine levels in the gerbil brain, Arch Int Pharmacodyn, 323, 85

Schran HF, 1996, The effects of renal and hepatic impairment on the disposition of the acetylcholinesterase inhibitor SDZ ENA 713, Pharm Res, 13, S‐428

10.1038/npp.1993.10

10.1176/ajp.141.11.1356

10.1097/00002093-199700112-00004

10.1016/0022-3956(75)90026-6

DeJong R., 1989, Measurement of quality‐of‐life changes in patients with Alzheimer's disease, Clin Ther, 11, 545

10.1056/NEJM199704243361704

Cutler NR, 1996, Alzheimer's disease. Therapeutic strategies, 387

10.1016/0024-3205(96)00081-1

10.1001/archinte.158.9.1021

10.1212/WNL.50.1.136

10.1016/S0011-393X(98)85048-0

Corey‐Bloom J., 1998, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, 55

10.1136/bmj.318.7184.633

Cutler NR, 1998, Antiemetic therapy for Alzheimer's patients receiving the cholinesterase inhibitor SDZ ENA 713, Clin Pharmacol Ther, 63, 188

10.1111/j.1532-5415.1998.tb01546.x

Steele CD, 1999, Recognition and management of early Alzheimer's disease, J Clin Outcomes Manage, 6, 52

10.2165/00002018-199819060-00004

10.1345/aph.18211

10.1016/S0140-6736(05)62221-0

10.2165/00023210-199911040-00004

Crismon ML, 1998, Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer disease, Pharmacotherapy, 18, 47S, 10.1002/j.1875-9114.1998.tb03878.x

10.1001/jama.281.15.1401

10.1177/089198879600900101

10.4088/JCP.v60n0510

10.2165/00023210-199911030-00001

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 20 Số 1

1-12

Thông tin tác giả